
First patients receive mRNA therapy for tumour-selective activation
Strand Therapeutics has dosed the first patients in its ASCENT-1 Phase I clinical trial of STX-003, an intravenously delivered self-replicating mRNA therapy designed to selectively express IL-12 within tumours while restricting expression in healthy tissue. This is the first clinical evaluation of Strand’s SignalLock genetic circuitry, designed… Read More



